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Background: Many studies have suggested that the immune response may play a crucial role in the progression of
hepatocellular carcinoma (HCC). Therefore, our aim was to establish a (i) functional culture of primary human tumor
hepatocytes and non-tumor from patients with hepatocellular carcinoma (HCC) and (ii) a co-culture system of HCC
and non-HCC hepatocytes with autologous peripheral blood mononuclear cells (PBMCs) in order to study in vitro
cell-to-cell interactions.
Methods: Tumor (HCC) and non-tumor (non-HCC) hepatocytes were isolated from the liver resection specimens of
11 patients operated for HCC, while PBMCs were retrieved immediately prior to surgery. Four biopsies were
obtained from patients with no liver disease who had surgery for non malignant tumor (normal hepatocytes).
Hepatocytes were either cultured alone (monoculture) or co-cultured with PBMCs. Flow cytometry measurements
for MHC class II expression, apoptosis, necrosis and viability (7AAD) were performed 24 h, 48 h and 72 h in
co-culture and monocultures.
Results: HCC and non-HCC hepatocytes exhibited increased MHC-II expression at 48h and 72h in co-culture with
PBMCs as compared to monoculture, with MHC II-expressing HCC hepatocytes showing increased viability at 72 h.
PBMCs showed increased MHC-II expression (activation) in co-culture with HCC as compared to non-HCC
hepatocytes at all time points. Moreover, CD8+ T cells had significantly increased apoptosis and necrosis at 48h in
co-culture with HCC hepatocytes as compared to monocultures. Interestingly, MHC-II expression on both HCC and
non-HCC hepatocytes in co-culture was positively correlated with the respective activated CD8+ T cells.
Conclusions: We have established an in vitro co-culture model to study interactions between autologous PBMCs
and primary HCC and non-HCC hepatocytes. This direct interaction leads to increased antigen presenting ability of
HCC hepatocytes, activation of PBMCs with a concomitant apoptosis of activated CD8+ T cells. Although, a partially
effective immune response against HCC exists, still tumor hepatocytes manage to escape.
Keywords: HCC/non-HCC-Hepatocyte-PBMCs co-cultures, CD8+ T lymphocyte activation, Apoptosis, MHC-II
expression* Correspondence: koskinasj@yahoo.gr
12nd Department of Internal Medicine, Medical School of Athens, University
of Athens, Hippokration Hospital, 114 Vas. Sofias Avenue, Athens 171 23,
Greece
Full list of author information is available at the end of the article
© 2013 Doumba et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Doumba et al. BMC Gastroenterology 2013, 13:17 Page 2 of 12
http://www.biomedcentral.com/1471-230X/13/17Background
The effective immune response against hepatocellular
carcinoma is of great importance in the progression and
clearance of the tumor. Many studies have shown that the
immune response against HCC is restrained and not effec-
tive [1-3]. Cytotoxic T lymphocytes (CTLs) play a central
role in induction of anti-tumor immunity. Indeed, a high
frequency of cytotoxic CD8+ T cells infiltrating cancer
tissue can be a favorable prognostic indicator in HCC [4].
However, the progression of tumors despite the presence
of infiltrating or peripheral cytotoxic CD8+ T cells suggests
that immunological tolerance is induced, at least in part,
by tumors.
Tumor-specific immune responses were observed in a
significant proportion of patients with HCC. However,
spontaneous clearance of established tumors by en-
dogenous immune mechanisms is rare [5]. The fact that
many tumor-associated antigens (TAA) are normal self-
constituents, the immune responses that may generate
are generally weak. Moreover, the pressure of the host
immune system may lead to the development of various
mechanisms by which the tumor cells escape from im-
mune attack [6].
The induction of MHC-II expression on hepatocytes
would it be a possible mechanism of inducing the defec-
tive immune response against many liver diseases inclu-
ding HCC. Several studies have reported that hepatocytes
express MHC II molecules and are able to activate CD4+
and CD8+ T cells [7-9].
Although, in vitro and in vivo studies have demo-
nstrated that hepatoma cells may express high levels of
both class I and class II molecules [10-12], little is
known about their potential immunogenicity [13-15].
Currently, there is no evidence on the immunologic out-
come of the direct interaction between malignant human
hepatocytes and circulating T lymphocytes in an in vitro
co-culture system. The existing liver sinusoid barrier, as
well as the complex liver microcirculation hinders exam-
ination of the direct interaction between these two cell
populations in vivo. Therefore, the establishment of a
human experimental in vitro co-culture system for the
study of the interaction between HCC hepatocytes and
PBMCs is of great importance since all the evidence
concerning the anti-tumor response to HCC is based on
animal models.
Here we report the establishment of a functional co-
culture system of HCC and non-HCC hepatocytes, iso-
lated from the transected liver specimens of patients
submitted to anatomic liver resection for primary HCC,
with autologous PBMCs in order to study their direct
effect. In addition, these two types of cells interact with
each other leading to increase MHC-II expression on both
HCC and non-HCC hepatocytes with a concomitant acti-
vation of CD8+ T cells, which finally become apoptotic.Methods
Patients
Eleven patients, 10 males and 1 female, age between 57–75
years with cirrhosis and early stage HCC have been submi-
tted to anatomic liver resection with curative intent;
5 patients had chronic HBV infection, 2 alcoholic liver
disease, 1 NASH and in 3 patients the reason of liver dam-
age could not be defined (cryptogenic). All patients have
been operated in the Surgical Unit of Hepatopancreatobi-
liary Diseases of the 1st Department of Propaedeutic
Surgery of the University of Athens, between December
2005 and December 2010. Consent has been retrieved from
our patients, while the protocol has been approved by the
Ethical and Scientific Committee of our Hospital. Liver
specimens (from tumor and non-tumor regions) and pre-
operative peripheral blood samples were obtained from all
our patients. Also, four biopsies were obtained from
patients with no liver damage who had surgery for non ma-
lignant tumors (healthy, normal hepatocytes).Isolation and culture of PBMCs
Prior to liver tissue resection 10 to 15 ml of autologous
peripheral blood was collected in EDTA tubes and PBMCs
were isolated by using Histopaque 1.077 g/ml (Sigma
Chemicals, Germany), as previously described [16]. The
resulted cell pellet (PBMCs) was resuspended in culture
medium containing DMEM-HAM F12 (Biochrom co,
Germany) supplemented with 1% FBS (Gibco BRL, USA),
0.25 mg/ml human insulin (Sigma Chemicals, Germany),
100 U/ml Pen/Strep, 50 μg/ml gentamycin (Sigma Chemi-
cals, Germany), 20 mM HEPES (Gibco BRL, USA) and
1.3 mM L-Glutamine (Biochrom co, Germany) and the
yield of PBMCs was determined by Neubauer enumeration.
The above culture medium was chosen after experi-
ments that were performed for both hepatocytes and
PBMCs, in order to find the optimal co-culture condi-
tions. Therefore, hepatocytes and PBMCs were maintained
in monocultures using different FBS concentrations 0%,
1% and 5% in DMEM-F12 supplemented with 0.25 mg/ml
human insulin, 100 U/ml Pen/Strep, 50 μg/ml gentamycin,
20 mM HEPES and 1.3 mM L-Glutamine for 7 days. The
viability of both hepatocytes and PBMCs after 7 days in
culture was high, always exceeding 75%. The optimum
FBS concentration for the culture medium was the 1%.
PBMCs were then plated in 60-cm culture dish until the
day of the co-culture experiment in 1% culture medium.Isolation and culture of HCC and non-HCC hepatocytes
Tumor liver specimens were obtained from the primary
tumor and non-tumor surrounding liver parenchyma and
transferred in ice-cold DMEM-F12 supplemented with
10% FBS. Hepatocyte isolation was performed based on
previous isolation protocol with modifications [17-19].
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Collagenase Type IV (Sigma Chemicals, Germany) and
filtered through a 70 μm cell strainer (BD, USA). The
pellet containing the liver cells was resuspended in ice-
cold DMEM-F12 with 20%FBS and triple centrifugation
at 81 g for 12 min at 4°C was performed in order to sep-
arate the purified hepatocyte population (pellet) from
the non-parenchymal cells (supernatant) [20].
The pellet contained the purified hepatocytes, as further
confirmed by light microscopy and by flow cytometric
analysis of the two hepatocyte specific markers Hep-Par 1
and albumin described in the next paragraphs. Next,
hepatocytes remained in culture for few hours in 60-mm
dishes without collagen I in order to achieve maximum
hepatocyte purity, by removing possible remaining non-
parenchymal cells. Then, we carefully removed the super-
natant containing the hepatocytes and 1 × 105 tumor and
non-tumor hepatocytes were placed in 24-well plates
coated with 5 μg/cm2 rat tail collagen type I (BD, USA) in
10% FBS culture medium and allowed to adhere for 48 h.
16 hours prior to co-culture experiment the hepatocyte
medium was removed and hepatocytes were washed twice
with 1 × PBS in order to remove the possible remaining
intrahepatic lymphocytes. Then, 1% FBS culture medium
was added to the hepatocytes. The same procedure was
performed for the normal liver biopsies.
Co-cultures of HCC and Non-HCC Hepatocytes with
PBMCs
After initial plating the culture medium was carefully
aspirated. The ratio of PBMCs (effector cells) to hepato-
cytes in co-cultures was 5:1. The ratio that was chosen
was based on data from the literature. Most studies that
involved co-culture of rat lymphocytes with autologous
hepatocytes used the ratio of 10:1 [21-23]. We thought
that a ratio of 5:1 would be more realistic to seek inter-
actions between HCC and non-HCC hepatocytes with
autologous peripheral immune cells.
PBMCs were collected and washed by centrifugation.
The cell pellet was resuspended in 1% FBS medium and
the appropriate number of mononuclear cells was added
in each well on top of the adhered hepatocytes.
PBMCs with HCC-hepatocytes as well as PBMCs with
non-HCC hepatocytes were cultured for 24 h, 48 h and
72 h. As control cultures tumor, non-tumor hepatocytes
and PBMCs were maintained in monocultures. The
same procedure was performed for the four normal he-
patocyte PBMCs co-cultures.
Expression of Hep Par-1 on hepatocytes by flow
cytometry
After isolation, normal, HCC and non-HCC hepatocytes
were stained for the hepatocyte specific marker Hep Par-1
in order to verify the purity of the hepatocyte population.Hepatocytes were fixed with 4% paraformaldehyde
(PFA) (Sigma, chemicals, Germany) and centrifuged in
1 × PBS (Cambrex co, USA). Hepatocytes were then per-
meabilized with 0.1% Triton X-100 (Sigma, chemicals,
Germany). Hep Par-1 antibody (Dako Cytomation DK)
(1:10 dilution) was incubated with Zenon ALEXA Fluor-
488 (Molecular Probes, UK) prior to addition to the cell
suspension. Then, hepatocytes suspension was incubated
with the Hep Par-1/Zenon ALEXA Fluor-488 antibody
mixture. The cells were then immediately analyzed by
using EPICS-XL MCL flow cytometer. Unstained cells
were used for the determination of the positive stained
hepatocyte population.Hep Par-1 immunocytochemistry
Cytospin preparations of hepatocyte’s suspension were
fixed with 4% PFA. Hepatocytes were washed with 6%
BSA (Sigma, chemicals, Germany) /0.2% Tween-20
(Sigma, chemicals, Germany) and 0.1% Triton X-100
was used for the permeabilization step. After a washing
step, blocking was performed with hydrogen peroxidase
(1:10 dilution). Hepatocytes were incubated with Hep
Par-1 antibody (1:5 dilution). The Envision Peroxidase
Detection Kit (Dako Cytomation, DK) was used in order
to detect Hep-Par-1. Hematoxylin was used for staining
the nuclei. Hepatocytes were then observed using micro-
scope Zeiss Axiostar plus.Analysis of MHC class II expression and viability of
tumour and non-tumour hepatocytes by flow cytometry
The supernatant from HCC non-HCC and normal co-
cultures, containing the PBMCs population was carefully
removed. The adhered hepatocytes were detached from
the wells by trypsinization at 24 h, 48 h and 72 h after
co-culture. In addition, hepatocytes were treated with
Stem Pro Accutase (Life technologies, Gibco, USA) in
order to avoid the formation of cell clusters.
The same procedure was performed for the monocul-
tures as well.
The hepatocyte pellets were triple stained with the
HLA-DR, DP, DQ-PE (Beckman Coulter, USA) (MHC
class II-PE) (surface), 7-AAD (BD, USA), as well as with
anti-human albumin-FITC (Dako Cytomation, DK)
(intracellular).
After isolation, hepatocytes were also stained with anti-
CD3 (Beckman Coulter, USA) and anti-CD14 (Beckman
Coulter, USA) monoclonal antibodies to further verify
their purity. MHC class II expression and 7-AAD measure-
ments were also performed after isolation. Hepatocytes
were immediately analyzed by flow cytometry. Unstained
hepatocytes were used as controls in order to determine
the autofluorescence of the cells and for setting the flow
cytometry protocol.
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CD8+ T cells were characterized from the total PBMCs
by staining them with the surface marker CD8-FITC
(Beckman Coulter, USA). The activation of both mono-
nuclear cells and CD8+ T cells was estimated by the
surface activation marker HLA-DR, DP, DQ [24]. Viabi-
lity, apoptosis and necrosis of PBMCs and CD8+ T lym-
phocytes was determined by 7-AAD staining. The above
measurements were performed by flow cytometry after iso-
lation, before co-culture experiment, 24 h, 48 h and 72 h
post co-culture. The same measurements took place for the
PBMCs monocultures as well.
As mentioned before the supernatants from tumor
and non-tumor co-cultures contained the PBMCs popu-
lation. Mononuclear cells were carefully aspirated from
each well and centrifuged. Cells were then triple stained
with the monoclonal CD8-FITC antibody, HLADR, DP,
DQ-PE and 7-AAD. Unstained PBMCs were used as
controls in order to determine the autofluorescence of
the cells.
Statistical analysis
All continuous variables are reported as the mean (± SD).
Paired comparisons between qualitative variables were
performed using the Wilcoxon sign rank test.. Data were
analyzed using SPSS 13.0 software. Pearsons correlation
coefficient was used to detect any positive or negative
correlations. P values <0.05 were considered statistically
significant.
Results
Viability and albumin expression of hepatocytes
The cell yield per gram of wet tissue after Collagenase
IV treatment varied between the different tissue samples
due to different underlying disease condition and age.
In average the cell yield was 7 × 106 for the HCC-HCC HEPAT
a
Figure 1 a) Representative photos of HCC hepatocytes in culture 48 h
stained with Hep Par-1 after isolation (immunocytochemistry) (magnihepatocytes and 5 × 105 for the non-HCC hepatocytes.
Immediately post-isolation the average viability was 90%
and 92% for HCC and non-HCC hepatocytes, respec-
tively. HCC and non-HCC hepatocytes expressed albu-
min protein at the level of 94% and 92%, respectively as
documented by means of flow cytometry, which remain
at the same levels throughout the experiment. Healthy
hepatocytes exhibited increased cell yield, viability and
albumin levels.
The morphological characteristics of HCC and non-
HCC hepatocytes remained grossly intact in culture
conditions, with viable hepatocytes presenting typical
and undamaged morphology as demonstrated by light
microscopy (Figure 1a). Freshly isolated hepatocytes
attached to collagen-coated dishes after initial plating
and formed semi-confluent monolayers within 48 h. Hep
Par-1 immunocytochemistry (Figure 1b), and flow cyto-
metry panels (Figure 2a,b) demonstrated hepatocellular
purity at the level of 85% to 90% for both HCC- and
non-HCC-cell cultures. The functionality of HCC and
non-HCC hepatocytes was measured by anti-human
albumin-FITC and was 92% and 89%, respectively
(Figure 2c,d). Negative staining for CD14, CD3 further
confirmed the absence of Kupffer cells and mononuc-
lears cells in the co-culture system (Figure 3a,b).MHC-II expression and viability of HCC and non-HCC
hepatocytes in co-culture with autologous PBMCs
After isolation, the MHC II expression on HCC hepato-
cytes was higher compared to non–HCC hepatocytes,
although this did not reach statistical significance (20%
vs 15%). On the other hand, MHC II expression on
hepatocytes derived from individuals with no liver dis-
ease had significant lower MHC II expression, ranged
between 3%-8%.OCYTES
b














HCC hepatocytes Non-HCC hepatocytes
HCC hepatocytes Non-HCC hepatocytes
85% 90%
92% 89%
Figure 2 Flow cytometry diagrams presenting: a) percentage of HCC-tumor hepatocytes and b) percentage of non-HCC hepatocytes
stained positive for Hep Par-1, using the secondary antibody Zenon-488, after isolation c) percentage of HCC-tumor and d) percentage
of non-HCC hepatocytes stained for human albumin-FITC.
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of MHC class II molecules on hepatocytes was further
increased compared to the single cultures at all time
points both for HCC and non-HCC hepatocytes.
For the HCC hepatocytes the respective difference reached
statistical significance at 48 h in co-culture compared to
monocultures (31.4 vs 23.8, p < 0.05), with a further increase
at 72 h (37.1 vs 28.1, p = 0.05) (Figure 4a, b, c).
Non-HCC hepatocytes also exhibited significant
increased MHC II expression 48 h post-co-culture
with PBMCs in comparison to mono-culture (21.9 vs
15, p < 0.05) (Figure 4d).Moreover, the expression of MHC class II molecules
on HCC hepatocytes was higher at all time points com-
pared to non-HCC hepatocytes both in co-cultures and
monocultures.
MHC II expression on hepatocytes from individuals
with no liver disease remained the same for both mono-
cultures and co-cultures with autologous PBMCs at all
time points (3-5%).
Interestingly, the viability of total non-HCC hepato-
cytes in co-culture was significantly lower at all time
points compared to the respective hepatocytes in




HCC hepatocytes HCC hepatocytes
Figure 3 After isolation tumor, non-tumor and normal hepatocytes were stained for CD3 and CD14 markers and analyzed by flow
cytometry in order to verify the purity of the hepatocyte culture was performed; representative flow cytometric diagram of
a) CD3-FITC and b) CD14-PE negative staining in tumor hepatocytes.
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contrast, the viability of total HCC hepatocytes had
not difference compared to the respective hepatocytes
in monocultures.
The viability of MHC II-expressing HCC hepatocytes
after 72 h in co-culture with PBMCs was significantly
higher compared to MHC II-expressing HCC hepato-
cytes in monoculture (11.5 vs 8.2 p < 0.05). In contrast,
MHC II-expressing non-tumor hepatocytes showed a
non-significant increased viability in co-culture com-
pared to their monocultures.Effects of HCC and non-HCC hepatocytes on PBMCs
and CD8+ T cells
The median expression of MHC II (activation) on PBMCs
from patients with HCC after isolation was 8%. PBMCs
exhibited an increase of MHC II expression in co-culture
with HCC as compared to non-HCC hepatocytes at all
time points. This difference in mononuclear cells activa-
tion was found to be statistically significant at 24 h (9.7 vs
7.4, p < 0.05) and 48 h (9.7 vs 7.9 p < 0.05) (Figure 5a, b, c).
Although, MHC II expression on PBMCs was elevated
in co-culture with tumor hepatocytes compared to
PBMCs monocultures, the respective differences did not
reach statistical significance (Figure 5c). In contrast, in
non-HCC co-culture there was no evidence of increased
MHC II expression on PBMCs at all time points, at least
with the activation markers that we have used.Also, no differences were observed concerning the
apoptosis and necrosis of activated and total peripheral
mononuclear cells in both HCC and non-HCC hepato-
cyte co-cultures compared with PBMCs monocultures.
Further, we examined the behavior of CD8+ T cell sub-
set from the total PBMCs population when co-cultured
with HCC and non-HCC hepatocytes. Therefore, in the
total PBMCs population we performed double staining for
CD8+ and MHC II expression (CD8 + MHC II+, pheno-
type of activated CD8 + T cells).
CD8+ T cells showed an increase of MHC II expres-
sion at all time points with a maximum at 72 h in co-
culture with HCC hepatocytes compared to PBMCs
monoculture although statistically was not significant
(Figure 6a, b). No significant activation of CD8+ T cells
was observed in co-culture with non-HCC hepatocytes
(Figure 6b).
7-AAD analysis of CD8+ T cells co-cultured with HCC
or non-HCC hepatocytes revealed an increased necrosis at
48 h (p < 0.05) as compared to control (PBMCs monocul-
tures). The activated CD8+ T cells (MHC II+) also showed
increased apoptosis and necrosis in co-culture with HCC
hepatocytes compared to controls especially at 48 h (0.18
vs 0.06, p = 0.046 and 0.15 vs 0.05, p < 0.05) (Figure 7). This
phenomenon was not observed in non-HCC co-cultures.
In the co-cultures of hepatocytes from individuals with
no liver disease with their autologous PBMCs no changes
were observed in activation or in viability status of either
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Figure 4 Representative flow cytometry scatterplot depicting the increased expression of MHC II on HCC hepatocytes (M region) a) 48
hours in co-culture with autologous PBMCs vs. b) 48 hours in monoculture. Representative graph showing the percentage of MHC II
expression on c) HCC and d) non-HCC hepatocytes in co-culture compared to hepatocyte monocultures. Time point zero (0 h) depicts MHC II
expression on hepatocytes directly after isolation.
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II expression on HCC and non-HCC hepatocytes and
activation of CD8+ T cells and PBMCs. Indeed, we found
that the MHC-II expressing HCC hepatocytes were posi-
tively correlated with the activated CD8+ T cells (CD8 +
MHC-II+) after 24 h and 48 h in HCC co-culture
(r = 0.947, p < 0.001 and r = 0.878, p = 0.021, respectively).
In addition, MHC-II expressing non-HCC hepatocytes
were also positively correlated with the activated CD8+ T
cells after 24 h and 72 h in co-culture (r = 0.0.925,
p = 0.008 and r = 0.948, p = 0.014, respectively).
Discussion
We have established a functional culture system for
HCC and non-HCC hepatocytes originating from surgi-
cal tissue specimens retrieved from HCC patients under-
going hepatectomy with intention to cure. 7-AAD and
human albumin staining indicated high viability and func-
tionality of hepatocytes (HCC, non-HCC and healthy)
in vitro, respectively. Hepatocyte purity after isolation with
the isolation protocol that we used was exceeding 95%
and was demonstrated by positive Hep Par-1 and negative
CD3 and CD14 immunostaining.Data from the literature indicate that the outcome of
interactions between tumor hepatocytes and immune cells
is critical for cancer regression or progression. There is lack
of appropriate models to address how human immune sys-
tem interacts with liver cancer cells. With the restriction of
human experimental system, most knowledge on liver can-
cer immunity is derived from animal models. So, we have
established an in vitro co-culture system of tumor and non-
tumor hepatocytes with PBMCs isolated from peripheral
blood drawn prior to resection in order to study their im-
munological interactions. With restrictions we believe that
this in vitro system will provide to us information of what
happens in vivo.
There are many scientific reports which have shown that
hepatocytes express MHC class II molecules and can act
as antigen presenting cells. Although, hepatocytes can
activate CD4+ and CD8+ T cells there are not able to
sustain this activation and to create an effective immune
response [7-9]. In addition, MHC molecules may be either
expressed de novo or up-regulated on a number of tumor
cells [25,26], but any relation to an effective presentation
of tumor antigen to T cells for stimulation and immuno-














































Figure 5 Flow cytometric diagrams showing total PBMCs activation (MHC-II expression) after 48 h in co-culture with a) HCC and b)
non-HCC hepatocytes. c) PBMCs exhibited significant activation at 24 h and 48 h when co-cultured with HCC hepatocytes compared to
non-HCC hepatocytes. Also, the activation of PBMCs in HCC co-culture was higher compared to PBMCs monoculture. Time point zero (0 h)
depicts activation of total PBMCs after isolation (0 h).
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molecules they avoid destruction by T cells [27-33].
Therefore, it is of great importance to study if primary
human neoplastic hepatocytes derived from HCC tumors
are able to express MHC class II molecules and have the
ability to act as antigen presenting cells when they are in
contact with peripheral blood mononuclear cells. If this is
true, HCC hepatocytes will be able to provide help to
immune cells, which are already defective, both in the
periphery and in the tumor microenvironment.Under normal conditions, hepatocytes do not express
MHC II molecules. However, hepatocellular MHC class II
expression has been reported in patients with hepatitis
[34,35], as well as in patients with HCC [10,11]. Further-
more, tumor hepatocytes from hepatoma cell lines express
MHC class II molecules and could act as antigen present-
ing cells [15,35]. Recent experimental evidence suggests
that the liver acts as a site of primary T-cell activation lead-
ing to functional impairment and premature death of cyto-







































0 h 24 h 48 h 72 h
activated CD8+ T cells HCC
COCUL
activated CD8+ T cells Non-
HCC COCUL
activated CD8+ T cells
monoculture
Figure 6 a) Representative flow cytometric diagram showing the increased expression of MHC class II on CD8+ T cells (activated) at
72 h HCC co-culture, b) CD8+ T cells exhibited higher activation at all time points compared to control PBMCs culture with a peak
at 72 h. Also, the activation of CD8+ T cells in both HCC and non-HCC cocultures was higher compared to CD8+ T cells activation after
isolation (0h).
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in vitro activation and proliferation of naive CD8+ T cells,
in the absence of CD4+ T cell co-stimulation, a clear indi-
cation that they possess the ability of antigen presentation.
Indeed, according to our results, HCC hepatocytes
exhibited high expression of MHC II on their surface
compared to non-HCC hepatocytes, expression that is
further enhanced upon co-culture with autologous
PBMCs at all time points. Increased MHC-II expression
was also observed in the non-HCC hepatocytes in co-
culture with PBMCs. However it has to be addressed
that the non–HCC hepatocytes are not really healthy as
they have derived from the HCC patients with under-
lying viral or other etiology chronic liver disease. In con-
trast, hepatocytes derived from individuals with no liver
disease had minimal MHC class II expression at the
beginning, which remained at the same low levels at all
time points in the monoculture or co-culture with
PBMCs system.With the respect to the effect of hepatocytes on
PBMCs our experiments showed that the expression of
MHC II on total PBMCs, which indicates an activation
status, was statistically higher in the presence of HCC
than non-HCC cells, particularly after 24 h and 48 h of
incubation. Furthermore, CD8+ T cell activation was
clearly seen after 72 h in the HCC co-culture system
than in the non-HCC system. No effect on MHC II ex-
pression on PBMCs and CD8+ T cells was observed in
the non-HCC co-culture system.
We next examine if the MHC-II expression on the
tumor and non-tumor hepatocytes in co-culture had any
correlation with the activation status of the CD8+ T cells
or the total PBMCs. Interestingly, we found that the ex-
pression of MHC-II on HCC hepatocytes was positively
correlated with the activated CD8+ T cells 24 h and 48 h
post-coculture. The same correlation was also true for
the non-HCC hepatocytes but at different time points
(24 h and 72 h post-coculture).Therefore, both MHC-II
HCC coculture HCC monoculture
0.48% 0.05%
a b
Figure 7 Flow cytometric diagrams showing the % of activated CD8+ T cells (CD8+ MHC II) that are apoptotic (D region) and necrotic
(E region) in a) HCC co-cultures and b) in control PBMCs cultures.
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culture was directly linked to the activated CD8+ T cells,
leading to effective immune response.
In agreement to these results is the fact that γ-
interferon (IFN-gamma) produced by T lymphocytes
that infiltrate the liver during the course of chronic
hepatitis induces MHC II expression and may endow
the hepatocytes with the capacity to perform accessory,
antigen-presenting, cell functions [35].
There is a possibility that a similar effect could also
happen in our in vitro co-culture system. In this respect
IFN-γ could possibly have a dual effect on HCC hepato-
cytes in co-culture; destruction of tumor cells and over-
expression of MHC II on them. This may also true for
the non-HCC virus infected hepatocytes. However, the
viability of MHC II-expressing HCC cells was signifi-
cantly higher in the co-culture system as compared to
the monocultures at 72 h, observation that was not
evident in non-HCC cells. In addition to the above
observation, the total viability of HCC hepatocytes in
co-culture remains unchanged, while the viability of the
respective non-HCC hepatocytes was significantly lower
at all time points compared to the respective monocul-
ture. Therefore, this further enhanced the idea that HCC
hepatocytes managed to survive and escape from the im-
mune attack in contrast to the respective non-HCC that
exhibited lower viability.
As a possible examination is the fact that increased ne-
crosis at 48 h in the total CD8+ T lymphocytes in the
HCC co-culture compared to PBMCs monoculture was
seen. More importantly, at 48 h, the activated CD8+ T
cells had undergone significant apoptosis and necrosis
compared to controls. However, the factors and themechanisms involved could be beyond the elimination
of the activated CD8+ T cells.
Indeed, several studies have shown that tumor cells
expressing decoy molecules, such as DcR3, can escape
FasL-dependent immune-cytotoxic attack. Thus, DcR3 is
considered to be one of the immune evasion systems for
tumor progression [37]. Also, it has been reported that
the number of regulatory T cells in the peripheral blood
and in the tumor microenvironment is increased and
that may exerts an inhibitory effect in the function of
the immune cells, including CD8+ T cells, [38], offering
an additional escape mechanism to HCC hepatocytes.
The elimination of CD8+ T cells here is not due to
death by neglect or lack of secondary activation signals
(cytokines etc.), as it was referred in other studies [7].
In our co-culture system, other immune cells are present
which could provide CD8+ T cells with secondary
signals and support CD8+ T cell activation something
that is verified from the increased activation of PBMCs
population.
Conclusions
In conclusion we have established, for the first time, an
in vitro model to study the interaction between autolo-
gous PBMCs and CD8+ T cells with primary HCC and
non-HCC hepatocytes.
Our results revealed a very interesting counteraction; an
increased expression of MHC II on both HCC and non-
HCC hepatocytes and activation of PBMCs followed by an
enhanced viability of MHC-II-expressing HCC cells with a
concomitant apoptosis of the activated CD8+ T cells. Fur-
ther experiments should take place in order to understand
the mechanisms of this interaction and benefit from this
Doumba et al. BMC Gastroenterology 2013, 13:17 Page 11 of 12
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cells and to activate the immune cells.
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